BPH Therapies in the AUA Guideline: A ChatGPT Pro Response
What does an explanation of AUA BPH therapies look like when generated by ChatGPT Pro using Astra? As part of an informal comparison with ChatGPT for Clinician, I used the same guideline-focused prompt in both; the Pro response below emphasizes how each treatment works.
This article was reproduced as generated using ChatGPT Pro with the Astra model in response to the prompt: “Tell me about the therapies in the AUA BPH guidelines and explain each one briefly.” It is shared for educational discussion and may contain errors or omissions. It does not replace the AUA guideline or clinical judgment.
The 2026 AUA BPH guideline covers three broad approaches: lifestyle changes, medications, and procedures/surgery. Treatment depends on symptom bother, prostate size and anatomy, bladder function, and preferences about recovery, sexual function, and future retreatment.
BPH means benign prostate enlargement. The guideline specifically addresses urinary symptoms attributed to BPH; urgency, frequency, or nighttime urination can also have other causes.
1. Lifestyle and behavioral management
Adjusting fluid timing, reducing caffeine or alcohol, and changing bladder habits can help manage symptoms. These approaches may be used alone when symptoms are manageable or alongside medication. They do not remove prostate tissue.
2. Medications
Therapy | Brief explanation |
Alpha blockers: tamsulosin, alfuzosin, silodosin | Relax muscle around the prostate and bladder outlet, making urination easier. Work relatively quickly but do not shrink the prostate. Possible effects include dizziness and changes in ejaculation. |
5-alpha reductase inhibitors (5-ARIs): finasteride, dutasteride | Gradually shrink an enlarged prostate by reducing DHT, a hormone involved in prostate growth. Take months to work and can reduce the risk of retention or surgery. Sexual side effects can occur. |
PDE-5 inhibitor: tadalafil 5 mg daily | Improves urinary symptoms and can also help erectile dysfunction. The guideline includes it whether or not erectile dysfunction is present. |
Anticholinergics / antimuscarinics | Calm bladder contractions to reduce urgency and frequency. Address bladder storage symptoms rather than prostate enlargement. Dry mouth, constipation, retention, and cognitive effects require consideration. |
Beta-3 agonists: mirabegron, vibegron | Help the bladder relax during filling, reducing urgency and frequency. Another option for predominant storage symptoms. |
Medication mechanisms and considerations are described in AUA and Urology Care Foundation resources.
Combination therapy may include:
Alpha blocker + 5-ARI: combines faster symptom relief with gradual prostate shrinkage.
Tadalafil + alpha blocker or 5-ARI: an option for selected patients.
Alpha blocker + antimuscarinic or beta-3 agonist: addresses both outlet-related symptoms and urgency/frequency.
The 2026 guideline also permits antimuscarinic or beta-3 therapy alone for appropriate patients with predominant storage symptoms.
3. Procedures and surgery
The names are easier to understand by looking at what each does to the obstructing tissue.
Therapy | What it does |
Prostatic urethral lift (PUL), UroLift | Permanent implants pull prostate tissue away from the urethra, opening the channel without removing tissue. |
Water vapor thermal therapy (WVTT), Rezūm | Injects steam into prostate tissue. The treated tissue gradually shrinks as the body absorbs it. |
Temporary implantable prostate device (TIPD), e.g., iTind | A temporary device reshapes the prostate’s urinary channel and is subsequently removed. |
Intraprostatic drug-coated balloon, Optilume BPH | Mechanically widens the channel and delivers paclitaxel to help maintain the opening. |
Prostate artery embolization (PAE) | An interventional radiologist blocks selected arteries supplying the prostate, causing it to shrink. |
Robotic waterjet treatment, Aquablation | Uses an image-guided waterjet to remove obstructing prostate tissue. |
Transurethral resection of the prostate (TURP) | Removes obstructing tissue through the urethra using an electrical cutting loop. Available as monopolar or bipolar TURP. |
Transurethral incision of the prostate (TUIP) | Makes small incisions to widen the outlet rather than removing substantial tissue. Mainly for small prostates. |
Photoselective vaporization (PVP), GreenLight | Uses laser energy to vaporize obstructing tissue. |
Bipolar transurethral vaporization (TUVP) | Uses electrical energy to vaporize tissue and open the channel. |
Anatomic endoscopic enucleation (AEEP), including HoLEP and ThuLEP | Separates and removes the enlarged inner prostate tissue through the urethra. HoLEP and ThuLEP use different lasers; other enucleation techniques are also included. |
Simple prostatectomy | Removes the enlarged inner portion through open, laparoscopic, or robotic surgery. Used for large prostates; it differs from removing the entire prostate for cancer. |
These procedures appear in the current guideline; the explanations describe their mechanisms, not equal-strength recommendations for every patient.
The main tradeoff: symptom relief and durability must be weighed against recovery and adverse effects, especially ejaculation changes. Tissue-preserving procedures may better support ejaculation preservation but can carry a greater chance of needing another BPH treatment. Procedures may also be appropriate without first exhausting medications, particularly with complications or a preference against medication.
proudP was built to give clinicians objective flow data across the entire BPH journey: at intake, through medical therapy, around a procedure, and into follow-up.
